Tagworks will present on the preclinical development of the first-in-class click-cleavable ADC TGW101, targeting non-internalizing pan-carcinoma marker TAG72; as well as TGW211, a first-in-class HER2-directed radioimmunoconjugate.  This presentation is part of the Engineering ADC Conjugates session on November 12, 2025, starting at 11.45 in Lisbon, Portugal. https://www.pegsummiteurope.com

Tagworks will present the IND-enabling data of the first in class click-cleavable ADC, TGW101, targeting non-internalizing pan-carcinoma marker TAG72

Tagworks will present how its Click-to-Release platform affords in vivo control over drug activity to address the limited therapeutic window and application scope of several targeted cancer therapies, applied to ADCs (i.e. TGW101, Tagworks’ lead clinical program) as well as targeted radiotherapies. The Antibody Engineering & Therapeutics Europe Conference will …

On June 19th, 2025, Marc Robillard will give a presentation about Tagworks’ Click-to-Release platform for ADCs and targeted radiotherapies at the Johnson & Johnson R&D Symposium on Antibody Conjugates in Beerse, Belgium. At this symposium exciting advancements in discovery and development of antibody-drug conjugates and targeted radiotherapies are explored by …

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors

Marc Robillard will present the progress of Tagworks click-cleavable radiotherapeutics program at the 6th Targeted Radiopharmaceuticals Summit in Amsterdam on December 5, 2024.

Madeira, September 4-6, 2024; www.antibodyseries.com

Boston, September 9-10, 2024; www.adc-partnering.com

Boston, August 20-22, 2024; www.adc-linker-conjugation.com

Marc Robillard will present Tagworks at the 24th BioEquity Europe on May 14 at 11:30 in San Sebastián, Spain.